29 completed, 10 recruiting, 5 not yet recruiting, 4 unknown. 22 Phase 1, 21 Phase 2, 11 Phase 3, 4 Not applicable.
Follow Chipscreen Biosciences, Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTC chidamide+benmelstobart+nab-paclitaxel+SBRT - BTC | Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 41 | 2026-11-01 | 2026-10-22 |
| Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets Chiglitazar/Metformin extended-release tablets under fasting conditions, Chiglitazar/Metformin extended-release tablets after a high-fat meal, multiple-dose of Chiglitazar/Metformin extended-release tablets - T2DM (Type 2 Diabetes Mellitus) | Phase 1 | Not yet recruiting | Chipscreen Biosciences, Ltd. | 28 | 2026-10-08 | 2026-04-06 |
| Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes SGLT-2 inhibitor and Chiglitazar, SGLT-2 inhibitor and Other Oral Antidiabetic Drugs (OADs) - T2DM (Type 2 Diabetes Mellitus) | Not yet recruiting | Chipscreen Biosciences, Ltd. | 3550 | 2026-07-18 | 2026-05-12 | |
| Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 1, Chiglitazar tablet, dose 1, Metformin extended-release tablet, dose 1 - T2DM (Type 2 Diabetes Mellitus) | Not applicable | Completed | Chipscreen Biosciences, Ltd. | 64 | 2026-07-09 | 2026-09-23 |
| A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma CS08399 - Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Chipscreen Biosciences, Ltd. | 186 | 2026-06-01 | 2026-05-13 |
| Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets treatment T (dose 1), treatment T (dose 2), treatment R (dose 1) - T2DM (Type 2 Diabetes Mellitus) | Not applicable | Completed | Chipscreen Biosciences, Ltd. | 24 | 2026-05-15 | 2026-09-23 |
| Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Chiauranib, Toripalimab Injection, Albumin-paclitaxel Injection - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Not yet recruiting | Chipscreen Biosciences, Ltd. | 558 | 2026-03-31 | 2026-03-03 |
| A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus Chiglitazar Placebo, Chiglitazar, vitamin E - MASH - Metabolic Dysfunction-Associated Steatohepatitis, T2DM (Type 2 Diabetes Mellitus) | Phase 2 | Recruiting | Shanghai Jiao Tong University School of Medicine | 300 | 2026-01-01 | 2026-06-03 |
| A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis CS32582 capsule（low dose） or matched placebo, CS32582 capsule（high dose） or matched placebo, CS32582 capsule（low dose） - Plaque Psoriasis | Phase 1 / Phase 2 | Recruiting | Chipscreen Biosciences, Ltd. | 220 | 2025-09-08 | 2025-09-10 |
| Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone), Tucidinostat, Placebo - Lymphoma, T-Cell, Peripheral | Phase 3 | Recruiting | Chipscreen Biosciences, Ltd. | 224 | 2025-08-12 | 2026-10-21 |
| Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors CS231295 - Neoplasms, Glioblastoma, Adult | Phase 1 | Recruiting | Chipscreen Biosciences, Ltd. | 102 | 2025-05-21 | 2025-05-25 |
| A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients Tucidinostat, Sintilimab, Bevacizumab - Colorectal Cancer | Phase 3 | Recruiting | Chipscreen Biosciences, Ltd. | 430 | 2024-12-06 | 2026-03-19 |
| Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma Chiauranib, Albumin-paclitaxel Injection, Gemcitabine Injection - Pancreatic Ductal Adenocarcinoma | Phase 2 | Active not recruiting | Chipscreen Biosciences, Ltd. | 42 | 2024-08-13 | 2026-10-23 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules CS32582 capsule, Placebo capsule - Healthy | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 112 | 2024-03-28 | 2024-12-03 |
| A Study of CS23546 in Subjects With Advanced Tumors CS23546 - Advanced Tumors | Phase 1 | Recruiting | Chipscreen Biosciences, Ltd. | 156 | 2024-03-27 | 2026-04-06 |
| A Study of NWY001 in Subjects With Advanced Solid Tumors NWY001 - Advanced Solid Tumor | Phase 1 | Recruiting | Chipscreen Biosciences, Ltd. | 196 | 2024-01-05 | 2024-07-16 |
| A Study of Chidamide With AZA in MRD Positive AML After Transplant chidamide and azacitidine - AML, Adult, Minimal Residual Disease | Not applicable | Recruiting | Guangdong Provincial People's Hospital | 60 | 2023-10-26 | 2023-10-27 |
| A Clinical Trial of CS12192 in Healthy Subjects CS12192 capsule, Placebo capsule - Healthy | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 108 | 2023-07-20 | 2024-02-07 |
| Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects. Chiglitazar, Empagliflozin, Atorvastatin - T2DM | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 48 | 2023-02-17 | 2023-06-15 |
| Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function Chiglitazar - Hepatic Impairment | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 24 | 2022-12-03 | 2024-05-28 |
Showing 20 of 51. Sign in to see all of them.
Diabetes Mellitus, Type 2 (8) · Recurrence (5) · Small Cell Lung Carcinoma (5) · Carcinoma, Non-Small-Cell Lung (4) · Ovarian Neoplasms (3) · Leukemia, Myeloid, Acute (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Non-Hodgkin (2) · Lymphoma, T-Cell, Peripheral (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Diabetes Mellitus (1) · Glioblastoma (1) · Hereditary Sensory and Autonomic Neuropathies (1)
chiauranib (16) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (14) · chiglitazar (10) · Cyclophosphamide (3) · Doxorubicin (3) · Paclitaxel (3) · Prednisone (3) · Vincristine (3) · Azacitidine (2) · Gemcitabine (2) · HBI-8000 (2) · 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid (1) · Atorvastatin (1) · Bevacizumab (1) · Capecitabine (1)
China (47) · Australia (1) · United States (1)
LiYan Miao (3) · Yuankai Shi (3) · Xiaohua Wu (2) · Bing Xu, M.D. (1) · Cabilia Pichardo, MD (1) · Caicun Zhou (1) · Hai Li, professor (1) · Hongrong Xu (1) · Huiqiang Huang, Ph.D. (1) · Huiqiang Huang, professor (1) · Jianan Huang (1) · Jun Zhu, Professor (1) · Li Zhang (1) · Linong Ji, Dr. (1) · Linong Ji, Prof. (1)
PMID 39123210, PMID 21565397, PMID 30642372, PMID 31036468, PMID 35547000, PMID 36654286, PMID 36654287, PMID 38162801, PMID 40842343, PMID 42018318, PMID 42148367, PMID 42150836, PMID 42439986